LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

LLY

1,027.42

+0.72%↑

JNJ

196.31

+0.27%↑

ABBV

233.1

-1.67%↓

UNH

320.97

-3.27%↓

AZN

88.78

+0.03%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Aperta

3.56 9.2

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.24

Massimo

3.6

Metriche Chiave

By Trading Economics

Entrata

1.9M

-68M

Vendite

-5.8M

42M

Margine di Profitto

-163.26

Dipendenti

570

EBITDA

25M

-41M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+38.46% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

60M

1.1B

Apertura precedente

-5.64

Chiusura precedente

3.56

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 nov 2025, 21:34 UTC

Utili

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Utili

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Utili

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Utili

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Utili

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Discorsi di Mercato

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Utili

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Utili

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Utili

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Acquisizioni, Fusioni, Takeovers

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Discorsi di Mercato

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Utili

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Utili

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Utili

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Utili

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Utili

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Utili

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Utili

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Utili

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Utili

Applied Materials 4Q Gross Margin 48.0% >AMAT

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

38.46% in crescita

Previsioni per 12 mesi

Media 4.5 USD  38.46%

Alto 5 USD

Basso 4 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.02 / 2.115Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat